Holen Sie sich die Stockscreener-App
9.28
2.36%
-0.2244
Schlusskurs vom Vortag:
$9.5044
Offen:
$9.5
24-Stunden-Volumen:
9,747
Relative Volume:
0.16
Marktkapitalisierung:
$254.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-102.09M
KGV:
-8.8381
EPS:
-1.05
Netto-Cashflow:
$-108.72M
1W Leistung:
-8.70%
1M Leistung:
-1.28%
6M Leistung:
+95.78%
1J Leistung:
+100.87%
1-Tages-Spanne:
$9.1312
$9.50
1-Wochen-Bereich:
$9.1312
$10.37
52-Wochen-Spanne:
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Vergleichen Sie DBVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.28 | 277.98M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Fortgesetzt | Goldman | Sell |
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold |
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy |
| 2019-12-16 | Eingeleitet | Citigroup | Buy |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Eingeleitet | Goldman | Buy |
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-03 | Eingeleitet | Barclays | Overweight |
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire
DBV Technologies Taps Healthcare Veteran as CHRO to Drive Commercial Evolution - Stock Titan
What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional
European Stocks In The US Finish With A Modest Rebound - Finimize
European ADRs Climb As Verona Pharma Leads Gains - Finimize
European ADRs Climb As Sequans Leads The Charge - Finimize
DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India
DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World
European Stocks Climb As ADRs Post Gains - Finimize
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Research Analysts Set Expectations for DBVT Q2 Earnings - Defense World
Lifesci Capital Upgrades DBV Technologies (NASDAQ:DBVT) to Strong-Buy - Defense World
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
DBV Technologies stock holds steady as JMP reiterates $21 price target - Investing.com
DBV Technologies Announces First Subject Screened in - GlobeNewswire
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why - Defense World
DBV Technologies to Participate in Upcoming EAACI Congress 2025 - The Manila Times
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - GlobeNewswire
DBV Technologies Secures Full Shareholder Support at Annual Meeting: Key Governance Updates - Stock Titan
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - GlobeNewswire
DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote - Stock Titan
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 By Investing.com - Investing.com South Africa
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities - Defense World
European ADRs Rise On S&P Europe Select Index - Finimize
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs Slip As US Index Notes Mixed Gains And Losses - Finimize
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
Combined General Meeting of June 11, 2025 - GlobeNewswire
DBV Technologies Sets Critical Shareholder Meeting: Key Documents Now Available - Stock Titan
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dbv Technologies Adr-Aktie (DBVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):